title: Outcome of Nephroblastoma Treatment According to the SIOP-2001 Strategy at a Single Institution in Argentina.
abstract: Wilms tumor (WT) is a disease with a good prognosis. The aim of this study was to evaluate the outcome of patients with WT, treated according to the SIOP-2001 strategy.
  
  
  
  A retrospective analysis of 141 consecutive patients with WT diagnosed at our institution between December 2001 and 2013 was performed.
  
  
  
  A total of 114 patients, median age 38.8 months (3 to 155 mo), were assessable for analysis. Fine-needle aspiration was initially performed in 88 patients (84.6%). Stage distribution was: I: 33%, II: 9.6%, III: 28%, IV: 14%, V: 14.9%. Six patients were stage III because of tumor spillage. The remaining patients received preoperative chemotherapy. Adjuvant chemotherapy was given without randomization, using vincristine-actinomycin for stage II and vincristine-doxorubicin-actinomycin plus radiotherapy for stage III. After a median follow-up of 52 months, 5-year overall survival and event-free survival were 91% and 85%, respectively. Overall survival according to stage was: I: 96%, II: 99%, III: 88%, IV: 78%, V: 90% (P=0.16). There was no significant difference in event-free survival (P=0.7). Seventy-eight (85.7%) were intermediate-risk and 11 (12%) were high-risk patients. Seventeen patients (14.9%) relapsed within 2 to 99 months (median 29.9 mo). Eight patients (7%) died of progressive disease. There were no treatment-related deaths.
  
  
  
  The SIOP-01 protocol proposes a treatment strategy that is feasible in our institution, achieving good results.
authors.affiliation: Departments of *Hemato-Oncology †Pathology ‡Surgery, Pediatric Hospital "Professor Dr. Juan P. Garrahan," Buenos Aires, Argentina.
authors.forename: Constanza
authors.initials: C
authors.lastname: Cafferata
authors.forename: Walter
authors.initials: W
authors.lastname: Cacciavillano
authors.forename: María L
authors.initials: ML
authors.lastname: Galluzzo
authors.forename: Paula
authors.initials: P
authors.lastname: Flores
authors.forename: Adriana
authors.initials: A
authors.lastname: Rose
authors.forename: Pedro
authors.initials: P
authors.lastname: Zubizarreta
mesh_terms: D000015:Abnormalities, Multiple / Q000453:epidemiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001118:Argentina; D017024:Chemotherapy, Adjuvant; D002675:Child, Preschool; D003131:Combined Modality Therapy; D015897:Comorbidity; D003609:Dactinomycin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D020360:Neoadjuvant Therapy; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000601:surgery; D009392:Nephrectomy; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D009396:Wilms Tumor / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary / Q000601:surgery
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin